RxDoctor Payments Data

Sue Brown, MD

Internal Medicine · Charlottesville, VANPI 1831277862

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Dexcom, Inc. accounts for 69.5% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for internal medicine clinicians in VA, where the typical reported total is $141.

$59in general payments, 2019–2025

Across 2 payments — averaging $29.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$41
  • Inari Medical, Inc.$18
$2,406,120in research payments, 2019–2025

Across 30 payments — averaging $80,204 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Insulet Corporation$1.1M
  • Tandem Diabetes Care, Inc.$970K
  • Dexcom, Inc.$353K

What the payments were for

  • Food & beverage$59100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Dexcom, Inc.1$41
Inari Medical, Inc.1$18

How this compares

$59 in reported general payments places this provider in the 35th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$38,054
Medicare patients
289
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Teriparatide25$54,409
OzempicSemaglutide22$34,467
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/728$32,607
JardianceEmpagliflozin16$25,727
MounjaroTirzepatide13$11,873
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$10,893
NovologInsulin Aspart40$8,268
HumalogInsulin Lispro30$6,123
Tresiba Flextouch U-100Insulin Degludec21$4,681
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,932
Novolog FlexpenInsulin Aspart16$2,728
SynthroidLevothyroxine Sodium38$2,113
Nano 2nd Gen Pen NeedlePen Needle, Diabetic20$1,621
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic17$1,518
Levothyroxine Sodium108$1,471

Paid to pharmacies, not to this prescriber.

Other internal medicine in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →